Amyotrophic Lateral Sclerosis Clinical Trials in Boston, Massachusetts

13 studies are recruiting for amyotrophic lateral sclerosis in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

   The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare …

   Stage

   Phase 3

   Ages

   18 to 80

   Site

   Sean M. Healey & AMG Center for ALS, Boston, Massachusetts

   Locations

   55 in total

   Run by

   Prilenia

   See if you can join NCT07322003 on ClinicalTrials.gov

2. Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

   PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration of Vtx-002 in participants with Amyotrophic Lateral Sclerosis (ALS). T…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, Boston, Massachusetts

   Locations

   11 in total

   Run by

   Vector Y Therapeutics

   See if you can join NCT07287397 on ClinicalTrials.gov

3. ASSESS ALL ALS Study

   The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is being funded by the National Institutes of Heal…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Brigham, Boston, Massachusetts

   Locations

   37 in total

   Run by

   St. Joseph's Hospital and Medical Center, Phoenix

   See if you can join NCT06578195 on ClinicalTrials.gov

4. PREVENT ALL ALS Study

   The ALL ALS Clinical Research Consortium is establishing research to collect a wide range of samples, clinical information and measurements from Amyotrophic Lateral Sclerosis (ALS) symptomatic, ALS gene carriers and control cohorts. This consortium is begin funded by the National Institutes of Heal…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Brigham, Boston, Massachusetts

   Locations

   32 in total

   Run by

   St. Joseph's Hospital and Medical Center, Phoenix

   See if you can join NCT06581861 on ClinicalTrials.gov

5. ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

   ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   27 in total

   Run by

   Mayo Clinic

   See if you can join NCT04363684 on ClinicalTrials.gov

6. Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

   The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

   Stage

   Not phased

   Ages

   18 to 80

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Leigh R. Hochberg, MD, PhD.

   See if you can join NCT05724173 on ClinicalTrials.gov

7. BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

   The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

   Stage

   Not phased

   Ages

   18 to 80

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   6 in total

   Run by

   Leigh R. Hochberg, MD, PhD.

   See if you can join NCT00912041 on ClinicalTrials.gov

8. EIM Via the Myolex mScan as an ALS Biomarker

   Amyotrophic lateral sclerosis (ALS) has been traditionally considered incurable and untreatable. But starting in the 1990s with the introduction of Riluzole, therapies are being discovered and ultimately approved for slowing disease progression. Many pharmaceutical companies continue to seek new th…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   6 in total

   Run by

   Beth Israel Deaconess Medical Center

   See if you can join NCT06491732 on ClinicalTrials.gov

9. Connect-One: Early Feasibility Study of Connexus® Brain-Computer Interface (BCI)

   The Connect-One Study is an early feasibility study to obtain preliminary device safety information for the Connexus Brain-Computer Interface (BCI). The Connexus BCI is intended to be used as: (1) an assistive communication device to decode imagined language correlates and speech for patients with …

   Stage

   Not phased

   Ages

   22 to 75

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   3 in total

   Run by

   Paradromics

   See if you can join NCT07357428 on ClinicalTrials.gov

10. A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)

    In this study, researchers will learn more about the safety of tofersen, also known as Qalsody®. This is a drug available for doctors to prescribe for participant with a certain type of amyotrophic lateral sclerosis, also known as ALS. This type is in participant who have a mutation in the superoxi…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Mass General Hospital -MGH, Boston, Massachusetts

    Run by

    Biogen

    See if you can join NCT07259980 on ClinicalTrials.gov

11. Intermuscular Coherence as a Biomarker for ALS

    The specific aims of this study are to: 1. Determine if a painless and quick measurement of muscle activity using surface electrodes can help with the diagnosis of ALS. Specifically, we ask if a measure of intermuscular coherence (IMC-βγ), when added to current diagnostic criteria (Awaji criteria),…

    Stage

    Not phased

    Ages

    20 to 90

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    4 in total

    Run by

    University of Chicago

    See if you can join NCT05104710 on ClinicalTrials.gov

12. Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

    The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Am…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    12 in total

    Run by

    Target ALS Foundation, Inc.

    See if you can join NCT05137665 on ClinicalTrials.gov

13. RAPA-501 Therapy for ALS

    RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Run by

    Rapa Therapeutics LLC

    See if you can join NCT04220190 on ClinicalTrials.gov